Nymox Pharmaceutical Co. (NASDAQ:NYMX) Director James George Robinson purchased 8,000 shares of the stock in a transaction on Monday, February 12th. The stock was bought at an average price of $3.27 per share, for a total transaction of $26,160.00. Following the completion of the transaction, the director now directly owns 3,107,850 shares of the company’s stock, valued at $10,162,669.50. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.
James George Robinson also recently made the following trade(s):
- On Thursday, February 8th, James George Robinson purchased 10,000 shares of Nymox Pharmaceutical stock. The stock was bought at an average price of $3.37 per share, for a total transaction of $33,700.00.
- On Friday, February 2nd, James George Robinson purchased 5,000 shares of Nymox Pharmaceutical stock. The stock was bought at an average price of $3.47 per share, for a total transaction of $17,350.00.
- On Thursday, January 18th, James George Robinson purchased 3,000 shares of Nymox Pharmaceutical stock. The stock was bought at an average price of $3.14 per share, for a total transaction of $9,420.00.
Shares of Nymox Pharmaceutical Co. (NASDAQ NYMX) traded down $0.04 during trading hours on Tuesday, reaching $3.24. The company’s stock had a trading volume of 139,200 shares, compared to its average volume of 234,899. Nymox Pharmaceutical Co. has a 52-week low of $3.00 and a 52-week high of $5.10. The company has a current ratio of 1.44, a quick ratio of 1.42 and a debt-to-equity ratio of 61.64.
A number of large investors have recently made changes to their positions in the business. Wedbush Securities Inc. grew its position in Nymox Pharmaceutical by 6.7% in the fourth quarter. Wedbush Securities Inc. now owns 277,177 shares of the biopharmaceutical company’s stock valued at $915,000 after acquiring an additional 17,485 shares during the period. BlackRock Inc. grew its holdings in shares of Nymox Pharmaceutical by 1.9% during the fourth quarter. BlackRock Inc. now owns 1,283,672 shares of the biopharmaceutical company’s stock worth $4,237,000 after purchasing an additional 23,444 shares during the last quarter. Goldman Sachs Group Inc. bought a new stake in shares of Nymox Pharmaceutical during the second quarter worth $117,000. Rhumbline Advisers bought a new stake in shares of Nymox Pharmaceutical during the second quarter worth $134,000. Finally, Northern Trust Corp bought a new stake in shares of Nymox Pharmaceutical during the second quarter worth $199,000. Hedge funds and other institutional investors own 5.91% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “James George Robinson Purchases 8,000 Shares of Nymox Pharmaceutical Co. (NYMX) Stock” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/13/james-george-robinson-purchases-8000-shares-of-nymox-pharmaceutical-co-nymx-stock.html.
Nymox Pharmaceutical Company Profile
Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.
Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.